RandomizEd ClinicAL triaL on the Efficacy and saFety of Incremental Hemodialysis (REAL-LIFE)

End Stage Renal Disease on Dialysis Clinical Trial

Official title:

RandomizEd ClinicAL triaL on the Efficacy and saFety of Incremental Hemodialysis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04360694
• Other study ID #: REAL LIFE
• Status: Recruiting
• Phase: N/A
• Start date: May 10, 2021
• Est. completion date: November 30, 2024

Study information

• Verified date: May 2022
• Source: Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
• Contact: Loreto Gesualdo, MD
• Phone: +390805594041
• Email: loreto.gesualdo[@]uniba.it
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Background: The thrice-weekly hemodialysis (HD) regimen is widely accepted as a standard prescription. The concept of incremental dialysis has been established as a possible alternative for patients with preserved diuresis and end-stage renal failure in need of HD. The main problems related to prescription of incremental HD are an arbitrary use of infrequent regimens and the lack of clear standards for incorporating residual kidney function (RKF) in the assessment of HD dose. Several models have been proposed for prescription of incremental dialysis. The latest, the variable target model (VTM), gives more clinical weight to the RKF and allows less frequent HD treatments at lower RKF. Despite increasing evidence derived from observational studies to support the use of incremental HD, RCTs are lacking and, therefore, urgently needed. Methods/Design: The Department of Nephrology, Dialysis and Transplantation of the Azienda Ospedaliero Universitaria Consorziale Policlinico, Bari, Italy and the EUDIAL Working Group of the European Renal Association - European Dialysis Transplant Association (ERA-EDTA) are starting a randomized clinical trial (RCT) in incident HD patients, whose name is "REAL LIFE", by using the acronym of its whole definition: RandomizEd clinicAL triaL on the effIcacy and saFety of incremental haEmodialysis. REAL LIFE is a pragmatic, prospective, multicentre, open label RCT, investigator-initiated, comparing the intervention arm (incremental HD) with the control arm (standard 3HD/wk). The trial, originally conceived by experts at the Division of Nephrology of the Miulli General Hospital, Acquaviva delle Fonti, Italy, consists in starting the HD treatment adopting the new incremental approach guided by the VTM. The primary outcome is the survival of kidney function, with the event defined as urinary output (UO) ≤ 100 mL/day, confirmed by a further collection after 2 weeks to exclude temporary illness. Discussion: REAL LIFE will enable the investigators to know with the highest level of scientific evidence the safety and efficacy of an incremental approach to the start of HD treatment.

Description:

The majority of dialysis patients are currently treated with a fixed dose thrice-weekly hamodialysis (HD) (3HD/wk). The 3HD/wk regimen has been assumed, until recently, almost as a dogma in the dialysis community. Incremental HD is based on the simple idea of adjusting its dose according to the metrics of RKF. REAL LIFE is a pragmatic, prospective, multicentre, open label RCT, investigator-initiated, comparing the intervention arm (incremental HD) with the control arm (standard 3HD/wk). A Variable Target Model (VTM) has been suggested, which gives more clinical weight to the RKF and allows less frequent HD treatments in patients with lower RKF. The investigators recommend to start and keep on with once-weekly HD, which should be possible until residual renal urea clearance (KRU) falls below 2.5 - 3.0 mL/min/35 L, i.e., glomerular filtration rate (GFR) ≈ 4 mL/min/1.73 m2. The primary outcome is the survival of kidney function, with the event defined as urinary output (UO) ≤ 200 mL/day, confirmed by a further collection after 2 weeks to exclude temporary illness. Secondary outcomes are: composite primary cardiovascular endpoint (cardiovascular death, non fatal myocardial infarction and/or or non fatal stroke); intima-media thickness of the carotid arteries; specific cardiomyopathy control; RKF preservation; survival of the patients; hospital admissions; anemia control; mineral and bone disorder control; middle molecules and RKF. Considering a type I error of 0.05 and type II error of 0.20, the study must enroll 49 patients in the conventional HD arm and 49 patients in the incremental HD arm, totaling 98 patients enrolled into the trial. Finally, under the assumption of an expected drop-out rate of 15%, 58 patients per group should be enrolled for a total of 116. The assessment of the key kinetic parameters as well as the guide to the selection of operative parameters, as required to get the required equilibrated Kt/V (eKt/V = 1.2), will be done by using SPEEDY, a spreadsheet prescription tool that uses essentially the same equations used by Solute Solver, the software based on the double pool UKM recommended by the 2015 KDOQI guidelines. SPEEDY is freely available at the European Nephrology Portal (ENP). The link is https://enp-era-edta.org/174/page/home. The control arm includes patients put on a thrice-weekly HD schedule, as detailed above. The dialysis dose (eKt/V) should be about 1.2. PICO question: Participants with CKD-EPI GFR ≤ 10 ml/min and daily urine output > 600 ml Intervention: one or two weekly hemodialysis (as detailed above) Comparator: three weekly hemodialysis (as per standard practice and as detailed above) Outcome: Residual renal function

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 116
• Est. completion date: November 30, 2024
• Est. primary completion date: November 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adults aged > 18 years
• Start of maintenance hemodialysis treatment due to advanced CKD stage 5D
• Glomerular filtration rate <= 10 mL/min/1.73 m2, as estimated by means of CKD-EPI formula.

Exclusion Criteria:

• Age < 18 years
• Acute kidney injury or acute on chronic kidney injury
• Tranferred from other dialysis modalities (peritoneal dialysis) or restarting HD after kidney transplant rejection
• eGFR lesser than 10 mL/min/1.73 m2
• UO < 600 mL/day
• Unable or unwilling to give informed consent.
• Unable to comply with trial procedures, e.g., collection of UO.
• Likely survival prognosis or planned modality or centre transfer < 6 months.
• Associated diseases: active neoplastic disease; refractory congestive heart failure (type IV NYHA) requiring high ultrafiltration volumes per session.

Related Conditions & MeSH terms

• End Stage Renal Disease on Dialysis
• Kidney Failure, Chronic

Intervention

Procedure:
• Incremental hemodialysis
58 patients will start renal replacement therapy (RRT) with an incremental hemodialysis (once-weekly or twice-weekly) regimen.
• Conventional hemodialysis
58 patients will start renal replacement therapy (RRT) with the standard (thrice-weekly) hemodialysis regimen.

Locations

Country	Name	City	State
Italy	Azienda Ospedaliero Universitaria Consorziale Policlinico	Bari

Sponsors (1)

Lead Sponsor	Collaborator
Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari

Country where clinical trial is conducted

Italy, 

References & Publications (5)

Basile C, Casino FG, Kalantar-Zadeh K. Is incremental hemodialysis ready to return on the scene? From empiricism to kinetic modelling. J Nephrol. 2017 Aug;30(4):521-529. doi: 10.1007/s40620-017-0391-0. Epub 2017 Mar 23. Review. — View Citation

Basile C, Casino FG; EUDIAL Working Group of ERA-EDTA. Incremental haemodialysis and residual kidney function: more and more observations but no trials. Nephrol Dial Transplant. 2019 Nov 1;34(11):1806-1811. doi: 10.1093/ndt/gfz035. — View Citation

Casino FG, Basile C. A user-friendly tool for incremental haemodialysis prescription. Nephrol Dial Transplant. 2018 Jun 1;33(6):1074-1075. doi: 10.1093/ndt/gfy081. — View Citation

Casino FG, Basile C. The variable target model: a paradigm shift in the incremental haemodialysis prescription. Nephrol Dial Transplant. 2017 Jan 1;32(1):182-190. doi: 10.1093/ndt/gfw339. — View Citation

Casino FG, Lopez T. The equivalent renal urea clearance: a new parameter to assess dialysis dose. Nephrol Dial Transplant. 1996 Aug;11(8):1574-81. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants whose kidney function remains >600 ml	The survival of kidney function is defined as a time to the event (anuria): the anuria is defined as urinary output (UO) = 200 mL/day, confirmed by a further collection after 2 weeks to exclude temporary illness	24 months
Secondary	Number of participants who develop cardiovascular death, non fatal myocardial infarction and/or or non fatal stroke (composite outcome)	Cardiovascular death, non fatal myocardial infarction and/or or non fatal stroke	24 months
Secondary	Mean value of intima-media thickness of the carotid arteries of participants at end of treatment and change from beginning to end of treatment	Echographic evaluation of intima-media thickness of the carotid arteries	12 and 24 months
Secondary	Value of left ventricular ejection fraction established with cardiac ultrasound at end of treatment and change from beginning to end of treatment	Ecocardiography reporting data on the left ventricular ejection fraction (LVEF)	12 and 24 months
Secondary	Value of residual kidney function (RKF) preservation established by the slope of decline of residual renal urea clearance	The rate of decline in RKF defined as the slope of decline of residual renal urea clearance	24 months
Secondary	Number of people who die	The follow-up time will be determined in days. It will be defined as the difference in days from the date of the end of the follow-up minus the date of the baseline visit. Events will be counted either as deaths (follow-up of less than 24 months) or as end of the follow-up	24 months
Secondary	Number of people who are hospitalized	The number of admissions will be registered.	24 months
Secondary	Value of hemoglobin in participants at end of treatment and change from beginning to end of treatment	The hemoglobin levels (in g/dl) will be measured.	Every months
Secondary	Value of serum phosphorus, calcium and parathyroid hormone in participants at end of treatment and change from beginning to end of treatment	Serum phosphorus and calcium levels (in mg/dl), and intact PTH (in pg/dl) will be measured.	Every months
Secondary	Value of serum beta 2 microglobulin (middle molecule) at end of treatment and change from beginning to end of treatment	The rate of change in serum beta 2 microglobulin in time will be evaluated	Every months
Secondary	Value of p-cresyl sulfate and inoxyl sulfate at end of treatment and change from beginning to end of treatment (uraemic toxins variation)	Variation of uremic toxins including p-cresyl sulfate and inoxyl sulfate	Every months